Comparative in Vitro Cellular Data Alone Is Insufficient to Predict Clinical Responses and Guide Choice of BCR-ABL Inhibitor to Treat Imatinib-Resistant Chronic Myeloid Leukemia

被引：0
|
作者：
Laneuville, Pierre [1 ]
DiLea, Clifford [2 ]
Mestan, Juergen [3 ]
Yin, Ophelia [2 ]
Woodman, Richard C. [2 ]
Manley, Paul [3 ]
机构：
[1] McGill Univ, Ctr Hlth, Montreal, PQ, Canada
[2] Novartis Pharmaceut, E Hanover, NJ USA
[3] Novartis Pharma AG, Basel, Switzerland
来源：
BLOOD | 2009年 / 114卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：211 / 211
页数：1
相关论文
共 50 条
  • [41] Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate
    E Jabbour
    H Kantarjian
    D Jones
    M Talpaz
    N Bekele
    S O'Brien
    X Zhou
    R Luthra
    G Garcia-Manero
    F Giles
    M B Rios
    S Verstovsek
    J Cortes
    Leukemia, 2006, 20 : 1767 - 1773
  • [42] Clinical outcome of chronic myeloid leukemia imatinib-resistant patients: do BCR-ABL kinase domain mutations affect patient survival? First multicenter Argentinean study
    Bengio, Raquel M.
    Riva, Maria E.
    Moiraghi, Beatriz
    Lanari, Emilio
    Milone, Jorge
    Ventriglia, Veronica
    Bullorsky, Eduardo
    de Tezanos Pinto, Miguel
    Murro, Hector
    Bianchini, Michele
    Larripa, Irene
    LEUKEMIA & LYMPHOMA, 2011, 52 (09) : 1720 - 1726
  • [43] RAPID INITIAL DECLINE IN BCR-ABL LEVELS IS ASSOCIATED WITH SUPERIOR RESPONSES IN IMATINIB-RESISTANT OR -INTOLERANT CHRONIC MYELOID LEUKEMIA PATIENTS IN CHRONIC PHASE (CML-CP) TREATED WITH NILOTINIB
    Stein, A.
    Shou, Y.
    Bottino, D.
    Chia, Y. L.
    Woodman, R.
    Martinelli, G.
    Hughes, T.
    Mueller, M.
    Beppu, L.
    Gottardi, E.
    Branford, S.
    Soverini, S.
    Goh, H.
    Hochhaus, A.
    Kim, D.
    Saglio, G.
    Radich, J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 56 - 56
  • [44] Detection of BCR-ABL T315i Mutation in Imatinib Resistant Chronic Myeloid Leukemia Patients
    Mardziah, M.
    Salwati, S.
    Azlin, I
    Hafiza, A.
    Farisah, Noor A. R.
    Noraesah, M.
    Tumian, N. R.
    Wong, C. L.
    Azma, R. Z.
    MEDICINE AND HEALTH-KUALA LUMPUR, 2019, 14 (01): : 145 - 156
  • [45] BCR-ABL KINASE DOMAIN MUTATION FREQUENCY IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS RESISTANT TO IMATINIB THERAPY
    Tikhonova, V.
    Misyurina, E.
    Kesaeva, L.
    Finashutina, Y.
    Krutov, A.
    Aksenova, E.
    Soldatova, I.
    Soldatkina, O.
    Ivanova, V.
    Novitskaya, N.
    Arshanskaya, E.
    Lazarev, I.
    Volkova, M.
    Pospelova, T.
    Konstantinova, T.
    Vysotskaya, L.
    Voloditcheva, E.
    Lapin, V.
    Davydkin, I.
    Turkina, A.
    Kolosheinova, T.
    Goryacheva, S.
    Chelysheva, E.
    Pristupa, A.
    Golubenko, R.
    Gavrilova, L.
    Volkova, S.
    Kuchma, G.
    Ovsyannikova, E.
    Zaklyakova, L.
    Kaplanov, K.
    Klitochenko, T.
    Misyurin, A.
    HAEMATOLOGICA, 2013, 98 : 548 - 548
  • [46] CD-200 induces apoptosis and inhibits Bcr-Abl signaling in imatinib-resistant chronic myeloid leukemia with T315I mutation
    Fang, Zhenghuan
    Jung, Kyung Hee
    Yan, Hong Hua
    Kim, Soo Jung
    Son, Mi Kwon
    Rumman, Marufa
    Lee, Hyunseung
    Kim, Ki Woon
    Yoo, Hye-Dong
    Hong, Soon-Sun
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2015, 47 (01) : 253 - 261
  • [47] Therapeutic application of small interfering RNA directed against bcr-abl transcripts to a patient with imatinib-resistant chronic myeloid leukaemia
    M. Koldehoff
    N. K. Steckel
    D. W. Beelen
    A. H. Elmaagacli
    Clinical and Experimental Medicine, 2007, 7 : 47 - 55
  • [48] A dual Bcr-Abl/Lyn tyrosine kinase inhibitor, NS-187, is a novel agent for imatinib-resistant leukemia.
    Kimura, S
    Naito, H
    Yokota, A
    Kamitsuji, Y
    Kawata, E
    Ashihara, E
    Nakaya, Y
    Naruoka, H
    Wakayama, T
    Asaki, T
    Niwa, T
    Hirabayashi, K
    Maekawa, T
    BLOOD, 2005, 106 (11) : 437A - 438A
  • [49] Therapeutic application of small interfering RNA directed against bcr-abl transcripts to a patient with imatinib-resistant chronic myeloid leukaemia
    Koldehoff, M.
    Steckel, N. K.
    Beelen, D. W.
    Elmaagacli, A. H.
    CLINICAL AND EXPERIMENTAL MEDICINE, 2007, 7 (02) : 47 - 55
  • [50] Dynamics and Characteristics of BCR-ABL Multiple Mutations In Tyrosine Kinase Inhibitor Resistant Chronic Myeloid Leukemia
    Kim, Dong-Wook
    Kim, Dongho
    Kim, Soo-Hyun
    Jootar, Saengsuree
    Goh, Hyun-Gyung
    Lee, Jeong
    Choi, Soo-Young
    Lee, Young-Seok
    Oh, Sang-Mi
    BLOOD, 2010, 116 (21) : 1412 - 1412
12345